Search Results 2191-2200 of 14718 for anti-TNF drugs

1. Ramandeep S. Takhter, Ph.D., M.S. - Mayo Clinic Faculty Profiles

   Drugs & Supplements A-Z · Health Books · Healthy Living Program · Mayo Clinic ... therapy. Cardiomyocytes are specialized cardiac muscle cells responsible ...

2. Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults - Mayo Clinic

   Drugs & Supplements A-Z · Health Books · Healthy ... By condition, treatment or drug name ... Human immunodeficiency virus (HIV)-infected patients on effective anti ...

3. Mayo Clinic Q&A podcast: Cardiac risks of off-label drugs to treat COVID-19

   Off-label means the drug has been approved by the Food and Drug Administration to treat a different condition. Some of the off-label drugs being used to treat ...

4. Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery - Mayo Clinic

   Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells. Cryosurgery, ...

5. Netarsudil (Ophthalmic Route) Description and Brand Names - Mayo Clinic

   Netarsudil eye drops is used alone or together with other medicines to lower pressure inside the eye that is caused by open-angle glaucoma or ocular (eye) ...

6. Cemiplimab-Rwlc (Intravenous Route) Proper Use - Mayo Clinic

   It is important for you to work closely with your doctor during your treatment. This medicine comes with a Medication Guide. Read and follow these instructions ...

7. Phase ll Study of Pirfenidone in Patients With RAILD - Mayo Clinic

   Any use of an approved anti-fibrotic medication within 28 days of screening. Participating Mayo Clinic locations. Study statuses change often. Please contact ...

8. Neomycin, Polymyxin B, And Hydrocortisone (Ophthalmic Route) Before Using - Mayo Clinic

   Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...

9. A Study to Evaluate CTX110 in Subjects with Relapsed or Refractory B-Cell Malignancies - Mayo Clinic

   For NHL patients: Use of systemic anti-tumor therapy or investigational agent within 14 days or 5 half-lives, whichever is longer, of enrollment. For B cell ...

10. A Study to Evaluate Ulixertinib to Treat Patients with Advanced Malignancies Harboring MEK or Atypical BRAF Alterations - Mayo Clinic

    Early clinical data have demonstrated anti-tumor activity with ulixertinib treatment and have identified specific groups of patients for whom additional ...